{
    "clinical_study": {
        "@rank": "20179", 
        "acronym": "RAMP-DCM", 
        "arm_group": [
            {
                "arm_group_label": "Controls", 
                "arm_group_type": "No Intervention"
            }, 
            {
                "arm_group_label": "Ranolazine", 
                "arm_group_type": "Experimental", 
                "description": "Initial dose is  375 mg bid. After 2 - 4 weeks the dose is increased to 500 mg bid and after another 2-4 weeks to 750 mg bid. In case of side effects the dose of the drug is to be decreased to the highest dose that the patient is still able to tolerate."
            }
        ], 
        "brief_summary": {
            "textblock": "Recent data suggest that areas of fibrosis and hibernating myocardium develop in patients\n      with non ischemic dilated cardiomyopathy. Ranolazine is a new drug, developed to releave\n      symptoms of angina in patients with stable coronary disease that is not suitable for\n      surgical or percutaneous revascularization.  It has been shown that  in patients with stable\n      coronary disease Ranolazine improves myocardial perfusion as shown with myocardial nuclear\n      imaging. The aim of this trial is to evaluate effects of ranolazine on myocardial perfusion\n      in patients with dilated cardiomyopathy."
        }, 
        "brief_title": "A Pilot Trial of Ranolazine to Treat Patients With Dilated Cardiomyopathy", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Dilated Cardiomyopathy", 
        "condition_browse": {
            "mesh_term": [
                "Cardiomyopathy, Dilated", 
                "Cardiomyopathies"
            ]
        }, 
        "detailed_description": {
            "textblock": "Recent data suggest that areas of fibrosis and hibernating myocardium develop in patients\n      with non ischemic dilated cardiomyopathy. Ranolazine is a new drug, developed to releave\n      symptoms of angina in patients with stable coronary disease that is not suitable for\n      surgical or percutaneous revascularization. The main mechanism of action of Ranolazine is\n      the inhibition of late  I(Na) thus decreasing the Ca++ load in the cardiomyocites.\n      Consequently oxygen consumption also decreases. It has also been shown that  in patients\n      with stable coronary disease Ranolazine improves myocardial perfusion as shown with\n      myocardial nuclear imaging. The aim of this trial is to evaluate effects of ranolazine on\n      myocardial perfusion in patients with dilated cardiomyopathy.\n\n      Primary end-point: To determine wheather Ranolazine improves perfusion of the myocardium in\n      patients with non-ischemic dilated cardiomyopathy.\n\n      Secondary end-points: To determine wheather Ranolazine improves patients' NYHA functional\n      class, excercise capacity, LV systolic and diastolic function and weather ranolazine affects\n      supraventricular and ventricular arrhythmia occurance/frequency."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  established diagnosis of non-ischemic dilated cardiomyopathy\n\n          -  EF < 35%\n\n          -  NYHA f.c. II - IV\n\n          -  Optimal medical management > 6 months\n\n          -  Age < 75 years  and  > 18 years\n\n        Exclusion Criteria:\n\n          -  known hypersensitivity to the medication\n\n          -  age > 75 years or < 18 years\n\n          -  EF > 35%\n\n          -  renal insufficiency (GF < 30)\n\n          -  liver dysfunction (liver tests > 3x the upper normal limit))\n\n          -  LQT syndrome\n\n          -  drugs that affect CYP3A4 metabolism (azoles, macrolides, calcineurin inhibitors\n             etc.)\n\n          -  dementia\n\n          -  active hemathological or malignant disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02133911", 
            "org_study_id": "AHFTX-UMCLJ-1"
        }, 
        "intervention": {
            "arm_group_label": "Ranolazine", 
            "intervention_name": "Ranolazine", 
            "intervention_type": "Drug", 
            "other_name": "Ranexa"
        }, 
        "intervention_browse": {
            "mesh_term": "Ranolazine"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 6, 2014", 
        "location": {
            "contact": {
                "email": "kokftx@gmail.com", 
                "last_name": "Gregor Poglajen, MD, PhD", 
                "phone": "+38615221148"
            }, 
            "facility": {
                "address": {
                    "city": "Ljubljana", 
                    "country": "Slovenia", 
                    "zip": "1000"
                }, 
                "name": "Advanced Heart Failure and Transplantation Programme, University Medical Center Ljubljana, Slovenia"
            }, 
            "investigator": [
                {
                    "last_name": "Gregor Poglajen, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Bojan Vrtovec, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Borut Jug, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Andra\u017e Cerar, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Mojca Bervar, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Slovenia"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effects of Ranolazine on Myocardial Perfusion in Patients With Dilated Cardiomyopathy", 
        "overall_contact": {
            "email": "gregor.poglajen@kclj.si", 
            "last_name": "Gregor Poglajen, MD, PhD", 
            "phone": "+38615228671"
        }, 
        "overall_contact_backup": {
            "email": "bojan.vrtovec@kclj.si", 
            "last_name": "Bojan Vrtovec, MD, PhD"
        }, 
        "overall_official": [
            {
                "affiliation": "Advanced Heart Failure and Transplantation Programme, University Medical Center Ljubljana, Slovenia", 
                "last_name": "Gregor Poglajen, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Advanced Heart Failure and Transplantation Programme, University Medical Center Ljubljana, Slovenia", 
                "last_name": "Bojan Vrtovec, MD, PhD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Slovenia: Republic of Slovenia National Medical Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To determine wheather Ranolazine improves perfusion of the myocardium in patients with non-ischemic dilated cardiomyopathy assesed by myocardial nuclear imaging.", 
            "measure": "Myocardial perfusion", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02133911"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University Medical Centre Ljubljana", 
            "investigator_full_name": "Gregor Poglajen", 
            "investigator_title": "MD, PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "To determine wheather Ranolazine improves patients' excercise capacity, assesed by 6' walk test", 
                "measure": "Excercise capacity", 
                "safety_issue": "No", 
                "time_frame": "1, 3 and 6 months"
            }, 
            {
                "description": "To determine wheather Ranolazine improves patients'  LV systolic and diastolic function, assesed by LVEF, TDI, LV longitudinal strain and strain rate", 
                "measure": "Left ventricular systolic and diastolic function", 
                "safety_issue": "No", 
                "time_frame": "1, 3 and 6 months"
            }, 
            {
                "description": "To determine wheather Ranolazine affects the occurence of supraventricular and ventricular arrhythmia occurance/frequency using 24 holter monitor.", 
                "measure": "Supraventricular and ventricular arrhythmias", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "source": "University Medical Centre Ljubljana", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Medical Centre Ljubljana", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}